Abstract
A bacterial natural product that is attracting considerable interest as a potential anticancer drug has been synthesized for the first time. The compound, epothilone A, and the related structure, epothilone B, seem to be more potent than the commercialized anticancer drug paclitaxel—and to have the same mechanism of action. The first total synthesis of epothilone A was carried out by chemistry professor Samuel J. Danishefsky, coworkers at Sloan-Kettering Institute for Cancer Research in New York City, and a graduate student at Columbia University [ Angew. Chem. Int. Ed. Engl, 35 , 2801 (1996)]. Danishefsky's group also has completed a second synthesis and has submitted a scientific paper describing it to a journal. Meanwhile, two other synthetic approaches to epothilone A will be published soon by an independent group led by chemistry professor K. C. Nicolaou at Scripps Research Institute, La Jolla, Calif., and at the University of California, San Diego. A third research group currently is ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
